Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director | June 01, 2022 | June 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TScan Therapeutics, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2032-05-31 | Direct | 9,146 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 9,146 · Balance 9,146 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2022 Filed Jun 3, 2022 20:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 9,146 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000899243-22-020961 · doc4.xml · derivative · entry 1 Harel Ittai · CIK 0001632710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,146 Underlying: Voting Common Stock · 9,146 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.